The Chemours Company (NYSE:CC) Stock Position Decreased by Bourgeon Capital Management LLC

Bourgeon Capital Management LLC cut its holdings in The Chemours Company (NYSE:CC) by 12.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,000 shares of the specialty chemicals company’s stock after selling 6,225 shares during the period. Bourgeon Capital Management LLC’s holdings in Chemours were worth $744,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Blue Trust Inc. lifted its holdings in Chemours by 166.9% in the 3rd quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company’s stock worth $26,000 after purchasing an additional 731 shares during the last quarter. Matrix Trust Co acquired a new stake in shares of Chemours in the third quarter worth $25,000. GAMMA Investing LLC grew its stake in Chemours by 99.7% in the 4th quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company’s stock valued at $26,000 after buying an additional 765 shares during the last quarter. Truvestments Capital LLC acquired a new position in Chemours during the 3rd quarter worth $35,000. Finally, Brooklyn Investment Group acquired a new position in shares of Chemours during the 3rd quarter worth about $37,000. 76.26% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, SVP Alvenia Scarborough sold 7,500 shares of the company’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $20.64, for a total transaction of $154,800.00. Following the transaction, the senior vice president now owns 16,645 shares of the company’s stock, valued at $343,552.80. This represents a 31.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.47% of the company’s stock.

Chemours Trading Up 2.6 %

Shares of Chemours stock opened at $19.90 on Wednesday. The Chemours Company has a 12-month low of $15.10 and a 12-month high of $32.48. The stock has a market capitalization of $2.97 billion, a P/E ratio of 39.80 and a beta of 1.83. The company has a 50-day simple moving average of $19.14 and a 200 day simple moving average of $19.69. The company has a quick ratio of 0.92, a current ratio of 1.73 and a debt-to-equity ratio of 6.05.

Chemours (NYSE:CC) last released its quarterly earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.32 by $0.08. Chemours had a return on equity of 29.48% and a net margin of 1.34%. The business had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.44 billion. During the same period in the prior year, the company earned $0.64 EPS. Chemours’s revenue for the quarter was up .9% on a year-over-year basis. Research analysts expect that The Chemours Company will post 1.19 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. The Goldman Sachs Group lowered their price objective on shares of Chemours from $24.00 to $21.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 7th. BMO Capital Markets lifted their target price on Chemours from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Monday, October 7th. Barclays boosted their price objective on Chemours from $21.00 to $23.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. Morgan Stanley reduced their target price on Chemours from $25.00 to $22.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $25.00 price target on shares of Chemours in a report on Thursday, December 12th. Five equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Chemours has an average rating of “Hold” and an average price target of $23.75.

Chemours Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.